Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO

Core Insights - BridgeBio Pharma has seen significant activity from institutional investors, with 99.85% of its stock currently owned by such entities, indicating strong institutional interest in the company [1] Institutional Investment - Jones Financial Companies Lllp acquired a new position worth $35,000 in the first quarter - CWM LLC increased its holdings by 29.8% in the second quarter, now owning 6,830 shares valued at $295,000 after purchasing an additional 1,569 shares - Allianz Asset Management GmbH grew its position by 57.7% in the second quarter, now holding 12,300 shares valued at $531,000 after buying an additional 4,500 shares - Virginia Retirement Systems ET Al purchased a new position valued at approximately $229,000 in the second quarter - Phoenix Financial Ltd. also acquired a new stake worth about $209,000 in the second quarter [1] Analyst Ratings - Goldman Sachs raised its price objective from $55.00 to $100.00, maintaining a "buy" rating - Cantor Fitzgerald increased its price target from $100.00 to $110.00, giving an "overweight" rating - JPMorgan Chase lifted its price target from $76.00 to $77.00, also rating it "overweight" - HC Wainwright raised its price objective from $90.00 to $100.00, maintaining a "buy" rating - Raymond James set a target price of $89.00 with an "outperform" rating - The consensus rating is "Moderate Buy" with an average price target of $82.05, supported by 22 buy ratings and one sell rating [2] Insider Activity - Director Randal W. Scott sold 10,000 shares at an average price of $75.46, totaling $754,600, resulting in a 46.32% decrease in his position - CEO Neil Kumar sold 40,000 shares at an average price of $74.40, totaling $2,976,000, leading to a 4.90% decrease in his ownership - In the last three months, insiders sold 176,121 shares valued at $13,009,631, with corporate insiders owning 18.20% of the company's stock [3] Stock Performance - BridgeBio Pharma's shares opened at $73.93, with a 12-month low of $28.33 and a high of $84.94 - The company has a market cap of $14.25 billion, a price-to-earnings ratio of -17.69, and a beta of 1.13 - The fifty-day simple moving average is $75.73, while the 200-day simple moving average is $63.79 [4] Company Overview - BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers - The company operates an integrated model that spans from target identification to commercialization [7] - Its pipeline includes various therapeutic modalities such as small molecules, biologics, and genetic therapies [8]